Status:
COMPLETED
Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
Lead Sponsor:
Sanofi
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
Evaluation of safety and efficacy of docetaxel in the treatment of advanced hormone refractory prostate cancer under the conditions of daily practise.
Eligibility Criteria
Inclusion
- The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
- Main criteria are listed hereafter :
- Patients with advanced prostate cancer, without previous chemotherapy, progressing on hormonal treatment, performance status 1 to 2
Exclusion
- Other cytostatic treatment, other malignity, severe comorbidity
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00280098
Start Date
January 1 2006
Last Update
December 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Prague, Czechia